In recent years, extensive effort has been made towards the diagnosis and therapeutics of lung cancer, which firmly ranks the first in terms of cancer incidence and cancer-associated mortality worldwide.
mechanism of carcinogenesis and metastasis is urgent for developing potential therapeutic targets and strategies.
FBXW7 (F-box and WD repeat domain-containing 7, FBXW7,
Cdc4, Ago, Sel10) is an evolutionarily conserved F-box protein, containing two essential functional domains (F-box and WD), which are necessary for function exertion. 3, 4 The F-box domain mediates Skyp1 binding for SCF complex formation, and the WD repeats as a substrate proteins-binding domain, form a β-propeller structure to bind substrates phosphorylated motifs (CPD, Cdc4 phosphodegron). 5, 6 Recently, it has been reported that FBXW7 mediated the ubiquitin-dependent proteolysis of multiple crucial oncoproteins such as Myc, c-Jun, Cyclin E and Notch1 most of which are involved in the diverse cellular processes, suggesting the suppressive role of degrading these oncoproteins. FBXW7 is commonly mutated in various types of tumours, and the overall mutation rate is approximately 6%. However, the precise mechanism of FBXW7 regulation of tumour initiation and progression is still unknown.
Epithelial-mesenchymal transition (EMT) is fundamental to malignant progression of cancer, 7, 8 which is a developmental process involving loss of apical polarity and obtaining of mesenchymal phenotype, contributing to increased migratory and invasive properties.
Also, EMT could help to generate and enrich cancer stem-like cells (CSC), the small subpopulation of cells with a high tumorigenic and self-renewal capacity and exist in various human malignancies, including NSCLC. [8] [9] [10] [11] To date, CSCs are thought to be responsible for renewal capacity by restraining Notch activity. 13 A study on gastric cancer showed that FBXW7 induced tumour growth arrest and EMT inhibition in part by targeting RhoA. 14 Our group found that miR-367 could target at FBXW7/Wnt signalling to control the stem cells' fates of NSCLC. 3 The regulatory mechanism of FBXW7 in tumorigenesis and progression is mainly realized via ubiquitin-mediated degradation of different oncoproteins, as were reported in these studies.
Snai1 is a critical transcription factor for EMT by binding to and sequentially inhibiting E-cadherin promoter, which reduced cell adhesion and promoted migratory capacity. In addition, current studies have shown that Snai1 is implicated in the regulation of chemoresistance and the emergence of cancer stem-like cell (CSC) phenotype. [15] [16] [17] The further elucidation of Snai1 in EMT and CSC provides a critical insight into the development of metastatic cancer and long-term recurrence. Several F-box proteins (Fbxw1, Fbxl14, Fbxl5, Fbxo11 and Fbxo45) that targeted Snai1 for degradation have been studied. Furthermore, some studies have reported that FBXW7 inactivation promoted EMT process through regulation of the Snail1 in various human cancers. 12, 14 However, the role of FBXW7-mediated Snai1 degradation remains unclear in NSCLC.
In this study, we planned to explore the role of FBXW7 in
NSCLCs' generation and progression, and hypothesized that FBXW7
is a potent prognostic factor and acts as a tumour suppressor in NSCLC partly by targeting Snai1 for ubiquitination and proteasomal degradation. and routinely incubated at 37°C in a humidified 5% CO2 incubator.
| ME THODS AND MATERIAL S

| Clinical samples and cell lines
The identity of cell lines was confirmed by short tandem repeatspolymerase chain reaction (STR-PCR) genotyping.
| Immunohistochemistry and immunofluorescence
The immunohistochemistry (IHC) staining was performed as previously described. Briefly, paraformaldehyde-fixed paraffin sections were deparaffinized and rehydrated. Antigen retrieval was performed in citrate buffer (Beyotime) at 100°C for 10 minutes. The sections were blocked with 3% hydrogen peroxide, followed by incubated with anti-FBXW7(1:100, Abcam, USA, ab105752) and antiSnai1 (1:50, CST, USA, #3879) antibody overnight at 4°C. Slides were then incubated with secondary antibodies for 1 hour at room temperature, developed using 3-diaminobenzidine (DAB) solution and counterstained with hematoxylin. The immunhistochemical staining of FBXW7 and Snai1 was evaluated by two pathologists in a blinded manner. The percentage of positive cells was divided into five rankings: 0, less than 10%; 1, 10%-30%; 2, 30%-50%; 3, more than 50%.
The expression of FBXW7 and Snai1 were defined as positive when the score was >3.
For immunofluorescence assay, A549 and HEK-293T cell lines (2.5 × 10 4 /well) were seeded on glass coverslips in 6-well plates for 24 hours. These cells were then fixed with 4% paraformaldehyde for 1 hour at room temperature and permeabilized with 0.1% Triton X-100 for 5 minutes. Next, the fixed cells were blocked with 5% Proteintech, USA, 51064-2-AP); anti-Ub (1:500 dilution; Santa Cruz, USA, sc-8017).
| Cell viability, migration and invasion
Cell viability assay was evaluated, using a Cell Counting Kit-8 (CCK- crystal violet and counted, using Image-pro plus software. 
| Wound healing assay
| Vector construction, transfection and reagents
Human FBXW7 and Snai1 cDNA were amplified by PCR and 
| Co-immunoprecipitation
For co-immunoprecipitation assay, beads (Dynabeads ® Protein G Immunoprecipitation Kit, Thermo Fisher, cat# 10007D) were mixed with the primary antibodies or lgG and shaken on a rotating shaker at 30 minutes at room temperature. Total protein lysates were extracted from cells, using NP40 cell lysis buffer, and the lysates were incubated with beads-Ab complex. After 1 hour incubation at room temperature, beads-Ab-antigen complex was collected by the magnet and washed 3 times, using 200 μL washing buffer. A quantity of 20 μL elution buffer and 10 μL SDS-PAGE sample buffer was added to beads-Ab-antigen complex before heating for 10 minutes at 70°C. The supernatant was collected and used for western blot analysis. 
| Statistical analysis
| RE SULTS
| Decreased FBXW7 is significantly correlated with poor survival outcomes in patients with NSCLC
We firstly investigated the expression of FBXW7 in 100 pairs of primary NSCLC tumour versus adjacent non-tumour tissues, using immunohistochemistry (IHC) staining. Representative IHC images of FBXW7 staining were shown in Figure 1A , and FBXW7 expression was significantly decreased in specimens of NSCLC, comparing to adjacent tissues ( Figure 1B ). This trend was further testified in randomly selected specimens by western blot ( Figure 1C ). The association between FBXW7 and clinicopathologic features were listed in Table 1 in detail. Chi-square test indicated that the lower FBXW7 expression in NSCLC was significantly associated with histology, later tumour stage and advanced differentiation degree. Moreover, gene set enrichment analysis (GSEA) on the RNA-sequencing data from public profiles helped to prove that higher FBXW7 expression was related with better survival in patients with NSCLC ( Figure 1D , left), which was also supported by Kaplan-Meier Plotter analysis (kmplot.com/analysis/) ( Figure 1D , right). Kaplan-Meier analyses and log-rank tests were also made to reveal the lower FBXW7
expression-associated poorer overall survival (P = .00241) and lower disease-free survival rates (P = .0351). These results indicated that FBXW7 may function as an anti-oncogene involved in the development and progression of human NSCLC ( Figure 1E ).
| FBXW7 inhibits proliferation, migration and EMT of NSCLC cells
To better understand the effect of FBXW7 on metastasis-related cell behaviours in NSCLC cells, we investigated the expression of FBXW7 in normal human bronchial epithelial cells of Beas-2b, and four paired NSCLC cell lines. Western blot analysis showed that FBXW7 level was lower in NSCLC cells than that in Beas-2b cells (Figure 2A ), to the same as the result shown in specimens study.
We constructed A549-Flag-FBXW7 cell with consistently FBXW7
expressing, and H1299-shFBXW7 cells with FBXW7-knockdown. Figure 3E -F, bottom).
As to the effects of FBXW7 on EMT process, the EMT markers and EMT-related transcription factors were qualified by western blot, which proved that FBXW7 could upregulate epithelial markers of Ecadherin and ZO-1, and decrease mesenchymal markers of N-cadherin and vimentin, as well as the EMT-related transcription factor of Snai1.
The opposite results were observed when slicing FBXW7 in H1299 cells ( Figure 3D ), demonstrating the functional cascade of FBXW7 in suppressing lung cancer cell proliferation, migration and EMT.
| FBXW7 restrains the acquisition of stem celllike phenotypes of NSCLC cells
Emerging evidence has clarified that EMT is directly relevant to Furthermore, the RNA and protein levels of FBXW7 were found to be strikingly down-regulated in sphere cells, comparing to the parental adherent cells ( Figure 3B ). Moreover, we performed GSEA analysis by using RNA-seq data of NSCLC tissues to elucidate the possible association between FBXW7 and ratio of CSCs,
and GSEA results showed that increased ratio of stem cell was increased greatly in FBXW7 lowly expressed tissues ( Figure 3C ).
To further validate the GSEA results, we detected the RNA levels of stem cell-associated markers of Oct4, Sox2, Nanog and Chemoresistance was considered to be the key stem cells' signature, and we chose two commonly used chemotherapy agents of cisplatin and sorafenib for sensitivity testing of two stable NSCLC cells. As expected, FBXW7 overexpressed cells were more sensitive to cisplatin and sorafenib induction of proliferation inhibition, and FBXW7 inhibition increased the resistance to cisplatin and sorafenib in a dose-dependent manner ( Figure 3G ).
| FBXW7 is inversely related to snai1 in NSCLC tissues
Previous studies have identified that multiple members of the F-box family were involved in the regulation of ubiquitination degradation of Snai1, while Snai1 has been reported to play important roles in EMT and stem cell phenotype of NSCLC. However, whether FBXW7 restrained these biological functions by inducing Snai1 ubiquitination and proteasomal degradation is still unknown. Thus, we firstly evaluated the relationship between FBXW7 and Snai1 in NSCLC tissues.
The correlation between FBXW7 and Snai1 was examined in serial sections of 100 NSCLC cases. IHC staining showed that Snai1 overexpression was detected in NSCLC samples compared with the corresponding non-tumorous tissues ( Figure 4A ). Besides, FBXW7
high expression was inverse correlation with Snai1 low expression in Case 3( Figure 4B , left). Inversely, FBXW7 low expression was associated with high Snai1 levels in Case 4 ( Figure 4B, left) . Although F I G U R E 1 FBXW7 expression and its clinical significance in NSCLC patients. A, Representative images of FBXW7 IHC staining in one pair of matched primary NSCLC samples and their corresponding non-tumour tissues (Scale bars: 50 μm). B, Corresponding semiquantifcation of FBXW7 expression in 100 pairs NSCLC specimens (***P < .0001). C, Western blotting of FBXW7 in 4 paired samples of NSCLC tissues (T) versus adjacent normal tissues (N). Levels were normalized to β-actin. D, Performance of GSEA based on publicly available NSCLC patient gene expression profiles (NCBI/GEO/GSE GSE18842; n = 91, left), Survival analysis of FBXW7 in lung cancer was performed at the online website Kaplan-Meier Plotter, using publicly available datasets (2015 version, Affy ID: 229419_at, right). E, Kaplan-Meier curves with univariate analysis (log-rank) for 5-year overall (P = .00214) and disease-free survival curves (P = .0351) of NSCLC patients based on their FBXW7 protein expression status 
| FBXW7 directly binds to and ubiquitylates snai1 for proteasomal degradation
To further investigate the regulatory relationship between software (UbiBrower) analysis revealed that the transcription factor of Snai1 contains one potential CPD, which includes the evolutionary conserved phosphoamino acids ( Figure 5A ).
Subsequently, we used a protease inhibitor (MG132) to confirm the FBXW7-mediated Snai1 degradation via the proteasomedependent pathway, and the protease inhibitor MG132 blocked the Snai1 degradation, suggesting that Snai1 might be degraded through a proteasome-dependent manner ( Figure 5B ). To explore whether Snai1 level is regulated at post-translational level,
qRT-PCR assay was applied and showed that no changes in Snai1 mRNA levels were observed after exogenous FBXW7 expression in A549 and 293T cells were conducted, consistent with the posttranslational regulatory model ( Figure 5C ). Immunofluorescence staining revealed that Snai1 was mainly positioned in the nucleus that co-localized with FBXW7. Moreover, ectopic expression of Flag-FBXW7 notably reduced the half-life of Snai1 by using the CHX chase assay in HEK239T and A549 cells.
We next sought to determine whether FBXW7 binds to Snai1 and leads to its ubiquitination.
To this end, we tested whether Snai1 interacted with FBXW7 using reciprocal coimmunoprecipitation 
| D ISCUSS I ON
FBXW7 is frequently mutated or depleted in various human cancers, and its dysfunctional mutation is firmly correlated with tumour progression. In this study, we initially detected FBXW7 expression in 100 pairs of NSCLC tissues and adjacent non-cancerous tissues, using immunohistochemistry and qRT-PCR, and results showing that FBXW7 was significantly lower in NSCLC tissues than that in paired non-cancerous tissues, which are similar to previous study. 18 Moreover, public GSEA data based clinical analyses showed that FBXW7 expression was significantly associated with later TNM stage and advanced histology. Lower FBXW7 expression was correlated with poorer patients' overall survival, and tended to have low disease-free survival rate.
Our previous studies showed that FBXW7 expression was associated with cell proliferation, cell cycle and apoptosis in NSCLC cells. 19 Nevertheless, the detailed mechanisms of FBXW7 in EMT and characteristics of NSCLC stem cells are rarely reported.
Mechanistically, we found that silencing FBXW7 in NSCLC cells promoted the EMT procedure and CSCs' self-renewal, which both contributed to the chemoresistance, and conversely, FBXW7 overexpression did the opposite, suggesting the pivotal role of FBXW7
in NSCLCs' EMT, and the renewal ability of subgroup of stem cell.
Importantly, re-sensitize the NSCLC to chemotherapeutics strongly proved that FBXW7 could be a potential biomarker for NSCLC therapy and prognostic prediction.
In vitro studies, we identified the existence of a physical interaction between FBXW7 and Snai1 in A549 and 293T cells by using immunofluorescent staining and co-immunoprecipitation.
Furthermore, our results indicated that FBXW7 targeted Snai1 and mediated ubiquitination of Snai1 in A549 and 293T cells, and that
MG132 treatment could block the FBXW7 overexpression-induced
Snai1 downregulation. According to these data, we confirmed that FBXW7 facilitates the ubiquitination of Snai1, and thus its subsequent proteasomal degradation. In most case, FBXW7 was reported to target substrates in a GSK3β-dependent manner. 20 Therefore, F I G U R E 7 FBXW7-induced suppression of NSCLC stemness and chemoresistance were partially reverted by Snai1. A, A549-Flag-FBXW7 cells and H1299-shFBXW7 cells that were transfected with HA-Snai1 and shSnai1, respectively, and subjected to Western blotting for NANOG, SOX2 and OCT4. B, Number of spheres per well were quantified on primary spheroid formation assay and secondary spheroid formation assay for A549-Flag-FBXW7 cells and H1299-shFBXW7 cells after transfected with HA-Snai1 and shSnai1, respectively (right panels). Left panels showed representative spheres. C, After restoring Snai1 expression, the sensitive of A549-Flag-FBXW7 cells and H1299-shFBXW7 cells to cisplatin and sorafenib was determined by MTT assay (*P < .05, ** P < .01) further investigation is required to confirm whether FBXW7 targets Snai1 also in a GSK3β-dependent manner.
We previously identified that loss of FBXW7 contributed to Wnt signalling activation through a LIN28B/Let-7-dependent manner in NSCLC stem cells. Meanwhile, it has been well established that Wnt/β-catenin activation induced both Snai1 mRNA and Snai1 protein expression via promoting GSK-3β inhibition and β-catenin stability, 21 implying that apart from FBXW7 induced-Snai1 degradation by ubiquitylation process, FBXW7 may also inhibit the expression of snail partly by inactivating Wnt signalling pathway.
In conclusion, our study identified that FBXW7 was lowly expressed in cancer tissues, compared to non-cancerous tissues, and reduced FBXW7 expression indicated poorer prognosis of patients with NSCLC. In vitro studies found that elevated FBXW7 expression inhibited EMT, CSCs' renewal ability, and re-sensitizes NSCLC cells to chemotherapeutics by targeting Snai1 for proteasomal degradation. Taken together, our study strongly suggested that FBXW7 may be a novel therapeutic and prognostic target of NSCLC, paving the way for possible pre-clinical application.
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